Use

This test is used to identify individuals with autosomal dominant multiple endocrine neoplasia type 2 (MEN2) syndrome by detecting single‑nucleotide variants, deletions, and duplications in the RET gene, which encodes the proto‑oncogene tyrosine‑protein kinase receptor Ret protein. Clinical indications include individuals with a clinical diagnosis of MEN2 (including MEN2A or MEN2B), medullary thyroid cancer (MTC), and primary C‑cell hyperplasia; informed consent and genetic counseling are strongly recommended.

Not provided.